Biohaven has surged driven by promising data from its troriluzole trials for spinocerebellar ataxia and ongoing OCD studies. Learn more about BHVN stock here.
Source link : http://www.bing.com/news/apiclick.aspx?ref=FexRss&aid=&tid=67099916b809407eb9abb414ddfa6eee&url=https%3A%2F%2Fseekingalpha.com%2Farticle%2F4726287-biohaven-a-complicated-tale&c=12590943479435301027&mkt=en-us
Author :
Publish date : 2024-10-11 09:20:00
Copyright for syndicated content belongs to the linked Source.